Loading...
Loading...
IVA| Name | Value |
|---|---|
| Revenues | 16.5M |
| Cost of Revenue | 0.6M |
| Gross Profit | 16.0M |
| Operating Expense | 63.7M |
| Operating I/L | -47.7M |
| Other Income/Expense | -6.8M |
| Interest Income | 0.0M |
| Pretax | -54.5M |
| Income Tax Expense | 0.6M |
| Net Income/Loss | -55.2M |
Inventiva S.A. is a clinical-stage biopharmaceutical company specializing in the development of oral small molecule therapies for various diseases, including non-alcoholic steatohepatitis (NASH) and mucopolysaccharidoses (MPS). Its lead product candidate, Lanifibranor, has completed Phase IIb clinical trial for NASH treatment, while Odiparcil, aimed at treating MPS VI subtype disease, has completed Phase IIa clinical trial. The company also has a pipeline of earlier stage programs in oncology and other diseases. Additionally, it has strategic collaborations with AbbVie and Boehringer Ingelheim International GmbH for the development of treatments for autoimmune diseases and idiopathic pulmonary fibrosis, respectively.
